jcxh-105
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 26, 2023 (NCT05871541)
Timeline
Indications
Mechanism of action
- Human herpesvirus 3Immunity, active
Human herpesvirus 3 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06581575 | Phase 2 | Sep 20, 2024 | Immorna Biotherapeutics, Inc., Tigermed Consulting Co., Ltd |
| NCT05871541 | Phase 1 | May 26, 2023 | ICON, Immorna Biotherapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immorna Biotherapeutics, Inc. | For profit | 2 | 2 | 2 | 2023 |
| ICON | For profit | 1 | 0 | 1 | 2023 |
| Tigermed Consulting Co., Ltd | For profit | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1